Newcastle disease viruses and uses thereof
AssigneesIcahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center
InventorsPeter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Jedd D. Wolchok
Life of this patent
Estimating the term…
Abstract
Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.
Claims9
A chimeric NDV comprising a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the transgene comprises the corresponding negative sense RNA sequence of the nucleotide sequence set forth in SEQ ID NO:61 or 26.
A chimeric NDV comprising a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:43 or 42.
Dependencies are inferred from the claim text.